Medical devices company Aran Biomedical revealed on Monday the appointment of Todd Blair as vice president of its Sales and Business Development (US) to meet and manage the growing demand for its implantable biomaterial product solutions.
Effective 1 July 2020, Blair will support, identify and develop the company's new business opportunities into sustainable and long-term partnerships, lead internal teams on proposal and product solution development as well as oversee the sales and business development activities in the US marketplace with a primary focus on the Orthopaedic, General Surgery and Vascular fields.
Most recently, Blair has served as vice president of Corporate Strategy at Heraeus Medical Components.
The company said Todd brings to the new position more than 20 years of experience in sales and business development within the life sciences contract manufacturing industry, with a focus on Bio-Textiles, Nitinol devices and polymeric components.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies